Lv5
970 积分 2025-03-13 加入
[2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis]
2小时前
待确认
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
2小时前
待确认
Safety and efficacy of jaktinib (a novelJAKinhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: Asingle‐arm,open‐label, phase 2, multicenter study
1个月前
已完结
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
1个月前
已完结
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
1个月前
已关闭
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
1个月前
已关闭
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
1个月前
已关闭
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
1个月前
已关闭
Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
1个月前
已完结
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data
1个月前
已完结
皖公网安备34019202002308
